Tipranavir: FDA advisory committee will meet May 19, hear experts, public comment.
At a one-day public meeting in Gaithersburg, Maryland (near Washington D.C.), the FDA will hear from experts and members of the public on tipranavir, an important new protease inhibitor expected to be approved soon.
D017277:Drug Approval / Q000331:legislation & jurisprudence*; D017320:HIV Protease Inhibitors; D011725:Pyridines; D011753:Pyrones; D013449:Sulfonamides; D014481:United States; D014486:United States Food and Drug Administration
D017320:HIV Protease Inhibitors; D011725:Pyridines; D011753:Pyrones; D013449:Sulfonamides; C107201:tipranavir